Rostil PlusSachet

Rostil Plus is a fixed-dose combination of a bulk-forming fibre laxative (ispaghula husk) and a musculotropic antispasmodic (mebeverine hydrochloride). It is indicated for:

• Irritable bowel syndrome (IBS) (guideline-supported use): symptomatic relief of abdominal pain/cramping, colonic spasm, bloating, and disturbed bowel habit (constipation, diarrhoea, or an alternating pattern) associated with IBS.
• Spastic colon / colonic spasm with associated constipation, where a bulking agent plus antispasmodic approach is appropriate.

Rostil Plus is intended for symptomatic relief and does not treat an underlying structural or infective cause of bowel symptoms; a physician should confirm the diagnosis before long-term use.

Each dose (typically supplied as a sachet of oral granules for reconstitution in water) of Ispaghula Husk + Mebeverine Hydrochloride generally contains:

• Ispaghula husk (psyllium husk) - a natural, hydrophilic bulk-forming fibre.
• Mebeverine hydrochloride - a synthetic musculotropic antispasmodic.

Exact strengths per sachet/dose vary by manufacturer; refer to the product label for the specific quantity of ispaghula husk and mebeverine hydrochloride in the pack being dispensed.

Rostil Plus combines two complementary mechanisms used together for irritable bowel syndrome: ispaghula husk, a natural soluble/insoluble fibre derived from Plantago ovata seed husks that absorbs water in the gut to form a soft, bulky gel, and mebeverine hydrochloride, a direct-acting smooth-muscle relaxant that reduces colonic spasm without causing the atony seen with some other antispasmodics.

The combination is formulated as granules that are dissolved in water and taken orally, allowing the fibre to bulk and normalise stool consistency while the antispasmodic component relieves the cramping pain often associated with IBS.

Rostil Plus belongs to a combined therapeutic class of Bulk-forming Laxatives (fibre supplements) and Gastrointestinal Antispasmodics (musculotropic smooth-muscle relaxants), used together for functional bowel disorders such as irritable bowel syndrome.

Ispaghula Husk + Mebeverine Hydrochloride exerts its effect through two distinct, complementary mechanisms:

Ispaghula husk

Ispaghula husk is a hydrophilic mucilloid that is not significantly absorbed or metabolised. On contact with water in the gastrointestinal tract it swells to form a viscous gel, which increases faecal bulk and water content, softens stool, and promotes more regular, easier bowel movements. This same bulking action can also help firm up loose stool in the diarrhoea-predominant pattern of IBS by normalising transit and stool form.

Mebeverine hydrochloride

Mebeverine hydrochloride is a musculotropic (direct-acting) antispasmodic. It acts locally on gastrointestinal smooth muscle, primarily by reducing sodium influx into smooth muscle cells, which lowers excitability and relieves spasm. Unlike anticholinergic antispasmodics, it has no significant effect on normal gut motility and lacks atropine-like side effects. Mebeverine is well absorbed after oral administration, extensively metabolised (largely to inactive metabolites), and excreted mainly in the urine, with a short plasma half-life.

To take Rostil Plus:

• Empty the entire contents of one sachet into a glass containing at least half a glass of water.
• Stir briskly and drink immediately, as the mixture can thicken quickly.
• Follow with an additional glass of water or other fluid.
• Take preferably shortly before a meal, in the morning and evening as directed.
• Maintain generous fluid intake throughout the day while taking Rostil Plus.

The ispaghula husk component of Rostil Plus is a bulk fibre that can physically bind to or delay/reduce the absorption of certain concomitantly ingested oral drugs if taken at the same time. Clinically relevant interactions include:

• Lithium: ispaghula-containing bulking agents may reduce the absorption and plasma levels of lithium; monitor lithium levels if co-administered, and consider separating dosing times.
• Digoxin and other narrow-therapeutic-index oral drugs: concurrent intake with bulk fibre may reduce absorption; separate administration by at least 1-2 hours where possible.

As a general precaution, other oral medicines should be taken at least one to two hours before or after Rostil Plus to minimise the risk of reduced absorption. No clinically significant interactions have been established for the mebeverine hydrochloride component at recommended doses.

Rostil Plus is generally well tolerated. Reported side effects include:

• Common: bloating, flatulence, abdominal distension, mild abdominal discomfort, particularly on starting treatment.
• Uncommon/rare: hypersensitivity reactions such as skin rash, itching, urticaria, and, rarely, angioedema.
• Rare but serious (usually related to inadequate fluid intake): intestinal or oesophageal obstruction from the ispaghula component if taken with insufficient fluid.

Patients should seek medical advice if severe abdominal pain, difficulty swallowing, chest discomfort, or signs of an allergic reaction occur while taking Rostil Plus.

Data on the use of Rostil Plus specifically during pregnancy and lactation are limited. As a general precaution, Rostil Plus should be used during pregnancy and breastfeeding only if clearly needed and if the potential benefit justifies the potential risk to the fetus or infant; a physician should be consulted before use.

Ispaghula husk is a non-absorbed bulk fibre and is generally considered to carry low systemic risk, but the mebeverine hydrochloride component has not been extensively studied in pregnancy, so combined use should be individualised by a physician.

When using Rostil Plus, observe the following precautions:

• Adequate fluid intake is essential. Rostil Plus must always be taken with plenty of water; insufficient fluid intake can cause the ispaghula component to swell in the throat or gut and worsen or precipitate obstruction (see Contraindications).
• Diabetes mellitus: some formulations of Rostil Plus may contain sugar or sweeteners; check the product label and use with caution in patients with diabetes.
• Children: mebeverine hydrochloride is generally not recommended for children under 10 years of age (see Use in Special Populations).
• Discontinue and seek medical advice if difficulty swallowing, chest pain, or worsening abdominal symptoms occur.
• Not a substitute for investigation of unexplained or persistent change in bowel habit, rectal bleeding, or unintentional weight loss - such symptoms require medical evaluation before starting Rostil Plus.

Overdose with Rostil Plus may present with exaggerated gastrointestinal effects (e.g. abdominal distension, bloating, or intestinal obstruction from the ispaghula component if fluid intake is inadequate) or, with large amounts of mebeverine hydrochloride, transient central nervous system excitation.

There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control centre; management is supportive and symptomatic, provided under medical supervision. Do not attempt unsupervised home treatment for a suspected overdose of Rostil Plus.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Children: Rostil Plus is generally not recommended for children under 10 years of age, as the safety and efficacy of the mebeverine hydrochloride component have not been established in this age group. Use in children should only be under specialist medical advice.

Elderly: no specific dose adjustment is required for elderly patients; standard adult dosing of Rostil Plus applies, with attention to adequate fluid intake and swallowing ability.

Renal/hepatic impairment: use Rostil Plus with caution and medical supervision, as specific dose-adjustment data are not well established.

Diabetic patients: check the sugar/sweetener content of the specific formulation of Rostil Plus being used.

The duration of Rostil Plus treatment should be individualised by the prescribing physician based on symptom response, typically reviewed after a few weeks of regular use. If symptoms of irritable bowel syndrome do not improve within 2-4 weeks, or if symptoms worsen, medical review is recommended rather than continuing Rostil Plus indefinitely without follow-up.

Bulk-forming Laxative (Fibre Supplement) + Gastrointestinal Musculotropic Antispasmodic

Ispaghula Husk + Mebeverine Hydrochloride works via two complementary actions: ispaghula husk absorbs water to form a bulky gel that normalises stool consistency and bowel transit, while mebeverine hydrochloride acts directly on intestinal smooth muscle to reduce spasm and cramping pain, without affecting normal gut motility.

Rostil Plus is generally not recommended for children below 10 years of age because the safety and efficacy of the mebeverine hydrochloride component have not been established in this age group. In older children where use is considered appropriate by a physician, dosing should be individualised and supervised, with particular attention to adequate fluid intake to reduce the risk of obstruction from the ispaghula husk component.